{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:28:54Z","timestamp":1793600934572,"version":"4.5.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Immunology & Cellular Therapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bict.2026.100055","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T23:19:57Z","timestamp":1776727197000},"page":"100055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Donor lymphocyte infusion as immune modulation after pediatric allogeneic transplantation"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5469-6889","authenticated-orcid":false,"given":"Dimitrios","family":"Filioglou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7064-6881","authenticated-orcid":false,"given":"Richard J.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1466-6965","authenticated-orcid":false,"given":"Emmanuel","family":"Katsanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bict.2026.100055_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.transci.2016.05.011","article-title":"Donor lymphocyte infusion after allogeneic stem cell transplantation","volume":"54","author":"Castagna","year":"2016","journal-title":"Transfus Apher Sci"},{"issue":"3","key":"10.1016\/j.bict.2026.100055_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.blre.2017.11.004","article-title":"Cell therapies for hematological malignancies: don't forget non-gene-modified t cells","volume":"32","author":"Grant","year":"2018","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.bict.2026.100055_bib3","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1016\/S2352-3026(24)00098-X","article-title":"Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT","volume":"11","author":"Pagliuca","year":"2024","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.bict.2026.100055_bib4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/14712598.2011.554811","article-title":"Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation","volume":"11","author":"Roddie","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.bict.2026.100055_bib5","first-page":"183.e1","article-title":"Outcomes after donor lymphocyte infusion in patients with hematological malignancies: donor characteristics matter","volume":"28","author":"Ros-Soto","year":"2022","journal-title":"Transpl Cell Ther"},{"issue":"9","key":"10.1016\/j.bict.2026.100055_bib6","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2013-08-523001","article-title":"Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion","volume":"123","author":"Bachireddy","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bict.2026.100055_bib7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1172\/JCI119601","article-title":"Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion","volume":"100","author":"Claret","year":"1997","journal-title":"J Clin Invest"},{"issue":"103","key":"10.1016\/j.bict.2026.100055_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adr0782","article-title":"Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy","volume":"10","author":"Maurer","year":"2025","journal-title":"Sci Immunol"},{"issue":"2","key":"10.1016\/j.bict.2026.100055_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.bict.2026.100055_bib10","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.bbmt.2020.02.006","article-title":"The role of donor lymphocyte infusion (DLI) in post-hematopoietic cell transplant (HCT) relapse for chronic myeloid leukemia (CML) in the tyrosine kinase inhibitor (TKI) era","volume":"26","author":"Schmidt","year":"2020","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"10.1016\/j.bict.2026.100055_bib11","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.bbmt.2015.03.012","article-title":"Donor lymphocyte infusions for chronic myeloid leukemia relapsing after allogeneic stem cell transplantation: may we predict graft-versus-leukemia without graft-versus-host disease?","volume":"21","author":"Radujkovic","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"10.1016\/j.bict.2026.100055_bib12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702555","article-title":"Donor leukocyte infusions in acute lymphocytic leukemia","volume":"26","author":"Collins","year":"2000","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"10.1016\/j.bict.2026.100055_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27950","article-title":"Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia","volume":"66","author":"Liberio","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2021012411","article-title":"How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy","volume":"141","author":"Biederstadt","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bict.2026.100055_bib15","first-page":"839.e1","article-title":"Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome","volume":"27","author":"Guillaume","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"11","key":"10.1016\/j.bict.2026.100055_bib16","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/JCMA.0000000000000992","article-title":"Donor lymphocyte infusion for prophylaxis and treatment of relapse in pediatric hematologic malignancies after allogeneic hematopoietic stem cell transplant","volume":"86","author":"Hou","year":"2023","journal-title":"J Chin Med Assoc"},{"issue":"10","key":"10.1016\/j.bict.2026.100055_bib17","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1007\/s00277-025-06662-x","article-title":"Transplantation strategy affects the risk of GvHD after prophylactic and preemptive donor lymphocyte infusion","volume":"104","author":"Koster","year":"2025","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.bict.2026.100055_bib18","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15691","article-title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT","volume":"184","author":"Schmid","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bict.2026.100055_bib19","doi-asserted-by":"crossref","first-page":"100016","DOI":"10.1016\/j.bict.2025.100016","article-title":"Donor lymphocyte infusions after HCT are associated with low risk of graft-versus-host disease in pediatric and young adult patients","volume":"1","author":"Suryaprakash","year":"2025","journal-title":"Blood Immunol. Cell. Ther"},{"issue":"4","key":"10.1016\/j.bict.2026.100055_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/ejh.70112","article-title":"Efficacy and safety of donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation in pediatric patients","volume":"116","author":"Walther","year":"2026","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41409-023-02137-7","article-title":"Prophylactic versus preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study","volume":"59","author":"Yang","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"10.1016\/j.bict.2026.100055_bib22","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41409-019-0695-x","article-title":"Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)","volume":"55","author":"Feliu","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.bict.2026.100055_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.572918","article-title":"Donor lymphocyte infusions after allogeneic stem cell transplantation in acute leukemia: a survey from the Gruppo Italiano Trapianto Midollo Osseo (GITMO)","volume":"10","author":"Patriarca","year":"2020","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.bict.2026.100055_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071278","article-title":"Donor lymphocyte infusion in the treatment of post-transplant relapse of acute myeloid leukemias and myelodysplastic syndromes significantly improves overall survival: a French-Italian experience of 134 patients","volume":"16","author":"Accorsi Buttini","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bict.2026.100055_bib25","article-title":"Donor lymphocyte infusion combined with azacitidine after allogeneic HSCT in pediatric AML: a single-center retrospective analysis","volume":"16","author":"Bica","year":"2025","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.bict.2026.100055_bib26","first-page":"330.e1","article-title":"Efficacy of azacitidine and prophylactic donor lymphocyte infusion after HSCT in pediatric patients with acute myelogenous leukemia: a retrospective pre-post study","volume":"29","author":"Booth","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"5","key":"10.1016\/j.bict.2026.100055_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14293","article-title":"Post-transplant strategies to improve relapse-free survival in childhood leukemia: whole blood donor lymphocyte infusions and lenalidomide for inducing graft-versus-leukemia effect","volume":"26","author":"Chandar","year":"2022","journal-title":"Pediatr Transpl"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2014.200","article-title":"Adoptive therapy with donor lymphocyte infusion after allogenic hematopoietic SCT in pediatric patients","volume":"50","author":"Gozdzik","year":"2015","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"10.1016\/j.bict.2026.100055_bib29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/08880018.2020.1829220","article-title":"Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia","volume":"38","author":"Huschart","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"issue":"11","key":"10.1016\/j.bict.2026.100055_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30659","article-title":"Prophylactic donor lymphocyte infusion after haploidentical hematopoietic cell transplantation and post-transplant cyclophosphamide for treatment of high-risk myeloid neoplasms in children: a retrospective study","volume":"70","author":"Qi","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s44313-025-00111-4","article-title":"Prophylactic donor lymphocyte infusions after first allogeneic hematopoietic stem cell transplantation in children with acute leukemia","volume":"61","author":"Wei","year":"2025","journal-title":"Blood Res"},{"key":"10.1016\/j.bict.2026.100055_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1335341","article-title":"Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation","volume":"15","author":"Koster","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.bict.2026.100055_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41409-024-02458-1","article-title":"Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation","volume":"60","author":"Mamez","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.bict.2026.100055_bib34","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41409-025-02555-9","article-title":"Current use of donor lymphocyte infusions after allogenic stem cell transplantation in Europe: a survey on behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT","volume":"60","author":"Santoro","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2019.219790","article-title":"Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT","volume":"105","author":"Dholaria","year":"2020","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.bict.2026.100055_bib36","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41409-025-02622-1","article-title":"HLA loss-mediated immune escape of acute leukemias in pediatric patients post haploidentical transplantation","volume":"60","author":"Arnold","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.bict.2026.100055_bib37","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"10.1016\/j.bict.2026.100055_bib38","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ajh.24949","article-title":"Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation","volume":"93","author":"Gilman","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.bict.2026.100055_bib39","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/ejh.14340","article-title":"Inferior overall survival after haploidentical donor lymphocyte infusions in relapsed myeloid neoplasms","volume":"114","author":"Benoit","year":"2025","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.bict.2026.100055_bib40","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/s41409-024-02312-4","article-title":"Safety but limited efficacy of donor lymphocyte infusion for post-transplantation cyclophosphamide-treated patients","volume":"59","author":"Shanmugasundaram","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"10.1016\/j.bict.2026.100055_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134939","article-title":"T cell optimization for graft-versus-leukemia responses","volume":"5","author":"Biernacki","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41409-022-01846-9","article-title":"Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC","volume":"58","author":"Chauvet","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.bict.2026.100055_bib43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/imt-2018-0104","article-title":"Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review","volume":"11","author":"Durer","year":"2019","journal-title":"Immunotherapy"},{"issue":"3","key":"10.1016\/j.bict.2026.100055_bib44","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41409-024-02475-0","article-title":"The BLIND study: blinatumomab and DLI approach for management of B-ALL relapse after allogeneic stem cell transplantation. A multicentric Italian experience","volume":"60","author":"Giammarco","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"22","key":"10.1016\/j.bict.2026.100055_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216105","article-title":"Blinatumomab redirects donor lymphocytes against CD19+ acute lymphoblastic leukemia without relevant bystander alloreactivity after haploidentical hematopoietic stem cell transplantation","volume":"24","author":"Mancusi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bict.2026.100055_bib46","doi-asserted-by":"crossref","DOI":"10.1177\/2040620721994348","article-title":"Concurrent application of blinatumomab and haploidentical donor leukocyte infusions for refractory primary mediastinal large B-cell lymphoma","volume":"12","author":"Smith","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"9","key":"10.1016\/j.bict.2026.100055_bib47","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/bmt.2016.104","article-title":"Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant","volume":"51","author":"Ueda","year":"2016","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib48","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1159\/000531834","article-title":"Combination of donor lymphocyte infusion and blinatumomab for B-cell lymphoblastic lymphoma relapse after allogeneic stem-cell transplantation","volume":"16","author":"Mori","year":"2023","journal-title":"Case Rep Oncol"},{"issue":"5","key":"10.1016\/j.bict.2026.100055_bib49","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s12185-024-03839-4","article-title":"A case of posttransplant isolated extramedullary relapse of acute lymphoblastic leukemia achieving durable treatment-free remission with blinatumomab and donor lymphocyte infusion","volume":"120","author":"Nishijima","year":"2024","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.bict.2026.100055_bib50","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1097\/MPH.0000000000001789","article-title":"Combination therapy with chemotherapy, donor lymphocyte infusion with concurrent blinatumomab in relapsed\/refractory acute precursor B-lymphoblastic leukemia","volume":"43","author":"Choi","year":"2021","journal-title":"J Pediatr Hematol Oncol"},{"issue":"12","key":"10.1016\/j.bict.2026.100055_bib51","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bict.2026.100055_bib52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bict.2026.100055_bib53","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-024-01626-6","article-title":"Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.bict.2026.100055_bib55","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/bloodadvances.2022008981","article-title":"CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany","volume":"7","author":"Bader","year":"2023","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.bict.2026.100055_bib56","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1182\/blood.2019001641","article-title":"Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bict.2026.100055_bib57","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jcyt.2024.11.016","article-title":"Post-transplant relapse in pediatric acute lymphoblastic leukemia in the era of CAR-T cell therapy. A multicenter analysis of Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular (GETH-TC) Pediatric Committee","volume":"27","author":"Gonzalez Vicent","year":"2025","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.bict.2026.100055_bib58","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29323","article-title":"CD19 expression in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab","volume":"68","author":"Mejstrikova","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.bict.2026.100055_bib59","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12185-019-02665-3","article-title":"Successful treatment of acute myeloid leukemia co-expressing NUP98\/NSD1 and FLT3\/ITD with preemptive donor lymphocyte infusions","volume":"110","author":"Mitani","year":"2019","journal-title":"Int J Hematol"},{"issue":"19","key":"10.1016\/j.bict.2026.100055_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241915019","article-title":"Novel approaches to treatment of acute myeloid leukemia relapse post allogeneic stem cell transplantation","volume":"24","author":"Liberatore","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.bict.2026.100055_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2169\/internalmedicine.1714-23","article-title":"Donor lymphocyte infusion for relapsed acute leukemia or myelodysplastic syndrome after hematopoietic stem cell transplantation: a single-institute retrospective analysis","volume":"63","author":"Ogasawara","year":"2024","journal-title":"Intern Med"},{"key":"10.1016\/j.bict.2026.100055_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2025.108153","article-title":"Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemia","volume":"160","author":"Ronnacker","year":"2026","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.bict.2026.100055_bib63","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/leu.2013.7","article-title":"Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation","volume":"27","author":"Schroeder","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bict.2026.100055_bib64","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.3324\/haematol.2022.282570","article-title":"Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial","volume":"108","author":"Schroeder","year":"2023","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bict.2026.100055_bib65","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41409-025-02552-y","article-title":"Donor lymphocyte infusions after HLA-identical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in acute myeloid leukemia patients","volume":"60","author":"Storck","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"10.1016\/j.bict.2026.100055_bib66","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.bbmt.2019.04.018","article-title":"Sorafenib therapy is associated with improved outcomes for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Xuan","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib67","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1186\/s12885-023-11259-6","article-title":"Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis","volume":"23","author":"Du","year":"2023","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.bict.2026.100055_bib68","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00277-020-04321-x","article-title":"Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group","volume":"100","author":"Schuler","year":"2021","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.bict.2026.100055_bib69","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00277-021-04398-y","article-title":"Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial","volume":"100","author":"Amit","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bict.2026.100055_bib70","article-title":"Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.bict.2026.100055_bib71","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.bict.2026.100055_bib72","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41409-022-01619-4","article-title":"Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation","volume":"57","author":"Zhang","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.bict.2026.100055_bib73","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s41409-020-01174-w","article-title":"Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience","volume":"56","author":"Bruzzese","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib74","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40364-025-00816-9","article-title":"Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Jiang","year":"2025","journal-title":"Biomark Res"},{"issue":"18","key":"10.1016\/j.bict.2026.100055_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184557","article-title":"Characteristics and outcome of FLT3-ITD-positive pediatric acute myeloid leukemia-experience of Polish Pediatric Leukemia and Lymphoma Study Group from 2005 to 2022","volume":"15","author":"Czoga\u0142a","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib76","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2006-03-005769","article-title":"Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation","volume":"109","author":"Meyer","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bict.2026.100055_bib77","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V91.10.3671","article-title":"Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant","volume":"91","author":"Alyea","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib78","first-page":"78","article-title":"Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation","volume":"87","author":"Baron","year":"2002","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib79","first-page":"53.e1","article-title":"Analysis of cell subsets in donor lymphocyte infusions from HLA identical sibling donors after allogeneic hematopoietic cell transplant","volume":"27","author":"Orti","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"10.1016\/j.bict.2026.100055_bib80","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/s41409-020-01128-2","article-title":"T-cell tracking, safety, and effect of low-dose donor memory T-cell infusions after \u03b1\u03b2 T cell-depleted hematopoietic stem cell transplantation","volume":"56","author":"Blagov","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"10.1016\/j.bict.2026.100055_bib81","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jcyt.2018.01.006","article-title":"Generation of alloreactivity-reduced donor lymphocyte products retaining memory function by fully automatic depletion of CD45RA-positive cells","volume":"20","author":"Muller","year":"2018","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.bict.2026.100055_bib82","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41409-020-0991-5","article-title":"Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation","volume":"56","author":"Maung","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.bict.2026.100055_bib83","doi-asserted-by":"crossref","DOI":"10.1007\/s11357-025-02050-5","article-title":"Adoptive T-cell therapies for persistent COVID-19 in immunocompromised patients: comparison of IFN-\u03b3 virus-specific T-cell therapy and CD45RA+ T-cell depleted donor lymphocyte infusion","author":"Gopcsa","year":"2026","journal-title":"Geroscience"},{"issue":"7","key":"10.1016\/j.bict.2026.100055_bib84","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41409-021-01232-x","article-title":"Safety and efficacy of the low-dose memory (CD45RA-depleted) donor lymphocyte infusion in recipients of \u03b1\u03b2 T cell-depleted haploidentical grafts: results of a prospective randomized trial in high-risk childhood leukemia","volume":"56","author":"Dunaikina","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"12","key":"10.1016\/j.bict.2026.100055_bib85","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jcyt.2024.07.007","article-title":"Safety and efficacy of high-dose memory CD45RO+ donor lymphocyte infusion in pediatric recipients after hematopoietic stem cell transplantation","volume":"26","author":"Gasior Kabat","year":"2024","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.bict.2026.100055_bib86","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1172\/JCI81229","article-title":"Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts","volume":"125","author":"Bleakley","year":"2015","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.bict.2026.100055_bib87","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1200\/JCO.21.01755","article-title":"Naive T-cell depletion to prevent chronic graft-versus-host disease","volume":"40","author":"Bleakley","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bict.2026.100055_bib88","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/bmt.2015.139","article-title":"Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignancies","volume":"50","author":"Triplett","year":"2015","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.bict.2026.100055_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2025.102176","article-title":"Novel CD62L depleted donor lymphocyte infusion with T-cell receptor alpha-beta depleted haploidentical hematopoietic stem cell transplantation in children","volume":"89","author":"Cheuk","year":"2025","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.bict.2026.100055_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104648","article-title":"CAR T-cell therapy landscape in pediatric, adolescent and young adult oncology - a comprehensive analysis of clinical trials","volume":"209","author":"Mart\u00ednez-Gamboa","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.bict.2026.100055_bib91","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bict.2026.100055_bib92","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41409-020-01140-6","article-title":"Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"56","author":"Hua","year":"2021","journal-title":"Bone Marrow Transpl"}],"updated-by":[{"DOI":"10.1016\/j.bict.2026.100071","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000}}],"container-title":["Blood Immunology & Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050597626000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050597626000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:55:42Z","timestamp":1793598942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050597626000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S3050597626000254"],"URL":"https:\/\/doi.org\/10.1016\/j.bict.2026.100055","relation":{},"ISSN":["3050-5976"],"issn-type":[{"value":"3050-5976","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donor lymphocyte infusion as immune modulation after pediatric allogeneic transplantation","name":"articletitle","label":"Article Title"},{"value":"Blood Immunology & Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bict.2026.100055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100055"}}